Saxon Interests Inc. Purchases 105 Shares of Eli Lilly and Company (NYSE:LLY)

Saxon Interests Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 31.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 444 shares of the company’s stock after purchasing an additional 105 shares during the period. Saxon Interests Inc.’s holdings in Eli Lilly and Company were worth $393,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Planning LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the 1st quarter valued at $8,896,000. HighPoint Advisor Group LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at $9,878,000. Finally, Leo Wealth LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at $3,355,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LLY shares. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Truist Financial restated a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Citigroup initiated coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Finally, Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Trading Up 0.4 %

LLY stock traded up $3.86 during mid-day trading on Wednesday, reaching $917.58. The company’s stock had a trading volume of 593,782 shares, compared to its average volume of 3,013,567. The company has a market cap of $872.07 billion, a price-to-earnings ratio of 135.45, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The business’s 50 day moving average price is $904.41 and its 200 day moving average price is $850.31. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.